Table 4

Subjects demographic and clinical characteristics

Characteristics

SJIA

Flare

SJIA

Quiescence

POLYJIA

Flare

POLYJIA

Quiescence


N1

22

24

17

8


Female/Male2

11/11

11/13

14/3

7/1


African-

American

1

2

1

1


Asian

3

3

0

0


Caucasian

8

10

11

4


Caucasian Hispanic

10

9

5

3


Median age (yr) at disease onset (range)

5.8 (1.7 to 15.7)

5.8 (1.4 to 15.7)

8.6 (1.2 to 15.1)

8.6 (1.2 to 15.1)


Median age (yr) at sample collection (range)

9.3 (3.5 to 16.6)

11.1 (2.4 to 18.9)

13.4 (5 to 18.7)

14.1 (6.1 to 19.2)


Median WBC (x103/ul)

(range)

13.3 (5.3 to 27.4)3

6.9 (3.4 to 11.8)

8.8 (4.9 to 15.1)

7.5 (5.6 to 9.8)


Median platelets (x103/ul)

(range)

461 (257 to 814)4

280 (170 to 400)

384 (211 to 512)5

283 (224 to 432)


Median ESR (mm/h)

(range)

81 (11 to 121)6

5.5 (0 to 18)

31 (7 to 78)7

9 (2 to 15)


Median joint count (range)

9 (1 to 28)8

0 (0 to 1)

25 (3 to 62)9

0 (0)


Median prednisone dose,

mg/kd/day (range)

0.01 (0 to 0.53)10

0 (0 to 1.1)

0 (0 to 0.1)

0 (0 to 1)


Methotrexate/

total no. samples (%)

8/22 (36%)

7/24 (29%)

10/17 (59%)

6/8 (75%)


Anti-TNF/total no. samples (%)

7/22 (32%)

9/24 (38%)

5/17 (29%)11

5/8 (63%)11


IL-1RA/total no. samples (%)

1/22 (5%)

2/24 (8%)

0/17

0/8


F, Flare; Q, Quiescent; SJIA F, systemic score of ≥ 1 and/or an arthritis score of ≥ B; POLY F, arthritis score of ≥ 1 (See Tables 1-3)

WBC: white blood count; ESR: erythrocyte sedimentation rate

1 31 unique SJIA patients, and 18 unique PolyJIA patients; 15 SJIA patients and 7 PolyJIA patients gave samples during flare and quiescence.

2 P < 0.05 (chi-square test)

Tests performed using Kruskal-Wallis with Dunn's multiple comparison test post test (3 to 9):

3 P < 0.0001 compared to SJIA Q and P < 0.05 compared to Poly Q

4 P < 0.0001 compared to SJIA Q and P < 0.01 compared to Poly Q

5 P < 0.05 compared to SJIA Q

6 P < 0.0001 compared to SJIA Q and P < 0.01 compared to Poly Q

7 P < 0.01 compared to SJIA Q

8 P < 0.0001 compared to SJIA Q and Poly Q

9 P < 0.0001 compared to SJIA Q and Poly Q

10 One patient received intravenous methylprednisolone pulse of 1 g daily for three days at the time of the sample.

11 This difference may reflect inclusion of subsets of patients who are anti-TNF responders and non-responders. This difference also raises the possibility that the gene signatures could be specifically influenced by differential response to this drug in these groups.

Ling et al. BMC Medicine 2012 10:125   doi:10.1186/1741-7015-10-125

Open Data